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Dear Editor: 
Cold agglutinin disease (CAD) is characterized by immunoglobulin M (IgM)-mediated 
hemagglutination in cold conditions and complement activation leading to extra- and intravascular 
hemolysis [1, 2]. Under conditions like infection, complement activation persists and intravascular 
hemolysis occurs by the formation of membrane attack complex (MAC). Therefore, eculizumab, 
an anti-C5 antibody is expected to be effective in suppressing hemolytic attacks in CAD. 
 Herein, we report a case of fulminant type primary CAD treated with eculizumab. 
A 39-year-old man was diagnosed with bacterial pneumonia by a family doctor and treated with 
antibiotics. Five days after the diagnosis, he was referred to our hospital on account of 
hemoglobinuria, malaise, hemolytic anemia, and acute kidney injury. He had severe anemia (Hb 
5.2 g/dL), increased indirect bilirubin (3.6 mg/dL) and lactate dehydrogenase (LDH, 4347 IU/L) 
levels, decreased haptoglobin (<10 mg/dL) concentration, renal dysfunction (serum creatinine 
2.99 mg/dL), and hemoglobinuria. Due to severe hemolysis and clotting of blood, red blood cell 
and reticulocyte counts could not accurately be assessed. In a direct Coombs test, only 
complement Coombs test yielded positive results. Paroxysmal nocturnal hemoglobinuria (PNH)-
type cells were not detected. Serum cold agglutinin titers were markedly elevated (> 8192 folds).  
 Based on the diagnosis of fulminant hemolytic crisis in CAD caused by bacterial 
pneumonia, we initiated heat retention, blood transfusion, and steroid administration, but the 
3 
hemolysis did not improve. Due to the worsening renal function, further increasing LDH level 
(>7000 IU/L), and rapidly deteriorating general condition in a few days, the decision was made to 
commence eculizumab at 900 mg once a week (Fig. 1). After the initial administration, rapid 
reduction in the LDH level and improvement in hemolysis were observed, and most of the 
laboratory data were normalized including serum creatinine levels one month after initiation of 
eculizumab. Although there were no decreases in agglutinin titers, eculizumab treatment was 
terminated after the fourth shot because of the stabilization of hemolysis and the marked 
improvement in general condition. Since then, the observation period has been more than ten 
months; cold agglutinin titers were decreased, and hemolysis has not recurred. 
Recently, the effectiveness of combination therapy using rituximab and bendamustine 
for the treatment of CAD has been reported [3]. However, a period of several months is required 
before the effect is noticeable, and immediate changes cannot be expected. Eculizumab is an 
antibody that specifically binds to the C5 complement protein and prevents intravascular 
hemolysis [4-6]. Theoretically, eculizumab is also expected to be effective for the treatment of 
hemolytic attacks in CAD. Although there are no clinical trials, its potential efficacy has been 
suggested in some case reports [7-9]. In the current case, complement activation triggered by 
pneumonia led to fulminant hemolytic anemia. Because renal failure and hemolysis progressed 
rapidly in our case, eculizumab was administered instead of rituximab. Suppression of 
complement activity by eculizumab was clear, which resulted in the reversal of the patient’s critical 
condition and rapid clinical remission. It is likely that hemolytic attacks in CAD are a good target 
of eculizumab, as anticipated. 
Figure Legend 
Fig.1 Effect of eculizumab in a patient with fulminant hemolytic anemia of primary cold agglutinin 
disease. PSL, prednisolone; LDH, lactate dehydrogenase; RBC, red blood cell; sCre, serum 
creatinine; *, Cold aggulutinin titers were saturated over 8192-fold. 
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